Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

ADAMIS PHARMACEUTICALS CORPORATION

(ADMP)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsOther languagesPress ReleasesOfficial PublicationsSector news

ADAMIS PHARMACEUTICALS CORP : Regulation FD Disclosure, Financial Statements and Exhibits (form 8-K)

07/13/2021 | 06:05am EDT

Item 7.01 Regulation FD Disclosure

On July 12, 2021, Adamis Pharmaceuticals Corporation (the "Company") posted an investor presentation to its website in connection with presentations that its executives plan to make and various investor meetings. The investor presentation is available under the "Events and Presentations" tab in the "Investors" section of the Company's website, located at www.adamispharma.com. A copy of the investor presentation is attached as Exhibit 99.1 to this Current Report on Form 8-K and incorporated into this Item 7.01 by reference.

The information in this Current Report on Form 8-K, including Exhibit 99.1 attached hereto, is being furnished and shall not be deemed "filed" for the purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), or otherwise subject to the liabilities of that Section, nor shall it be deemed incorporated by reference into any filing of the Company under the Securities Act of 1933, as amended, or the Exchange Act, whether made before or after the date hereof, regardless of any general incorporation language in such filing, except as may be expressly set forth by specific reference in such filing or document. Item 7.01 of this Report and the furnishing of the attached presentation is not an admission as to the materiality of any information therein. The information contained in the presentation is summary information that is intended to be considered in the context of more complete information included in the Company's filings with the U.S. Securities and Exchange Commission and other public announcements that the Company has made and may make from time to time by press release or otherwise. Except to the extent required by applicable law, the Company undertakes no duty or obligation to update or revise the information contained in this report or in the presentation.

Item 9.01 Financial Statements and Exhibits

(d) Exhibits.



Exhibit No.      Exhibit Description

  99.1           Investor Presentation dated July 2021
104              Cover page interactive data file (embedded within the Inline XBRL
                 document).

© Edgar Online, source Glimpses

All news about ADAMIS PHARMACEUTICALS CORPORATION
09/20NORTH AMERICAN MORNING BRIEFING : Stock Futures -3-
DJ
09/20ADAMIS PHARMACEUTICALS CORPORATION(N : ADMP) added to S&P Global BMI Index
CI
09/13ADAMIS PHARMACEUTICALS : Departure of Directors of Certain Officers; Election of Directors..
PU
09/13ADAMIS PHARMACEUTICALS CORP : Change in Directors or Principal Officers (form 8-K)
AQ
09/13Adamis Pharmaceuticals Corporation Announces Resignation of Roshawn A. Blunt as Directo..
CI
09/02ADAMIS PHARMACEUTICALS : Begins Dosing Patients in Phase 2/3 Trial of Tempol to Treat COVI..
MT
09/02Adamis Pharmaceuticals Doses First Patients in Phase 2/3 Clinical Trial for Tempol in t..
GL
09/02Adamis Pharmaceuticals Corporation Doses First Patients in Phase 2/3 Clinical Trial for..
CI
08/30NORTH AMERICAN MORNING BRIEFING : Stock Futures -3-
DJ
08/24ADAMIS PHARMACEUTICALS : 8-K (Form 8-K)
PU
More news
Financials (USD)
Sales 2021 22,0 M - -
Net income 2021 -24,0 M - -
Net Debt 2021 - - -
P/E ratio 2021 -6,18x
Yield 2021 -
Capitalization 156 M 156 M -
Capi. / Sales 2021 7,11x
Capi. / Sales 2022 15,6x
Nbr of Employees 130
Free-Float 98,6%
Chart ADAMIS PHARMACEUTICALS CORPORATION
Duration : Period :
Adamis Pharmaceuticals Corporation Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends ADAMIS PHARMACEUTICALS CORPORATION
Short TermMid-TermLong Term
TrendsBullishBullishNeutral
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus HOLD
Number of Analysts 1
Last Close Price 1,05 
Average target price
Spread / Average Target -
EPS Revisions
Managers and Directors
Dennis J. Carlo President, Chief Executive Officer & Director
David C. Benedicto Chief Financial & Accounting Officer
Richard C. Williams Chairman
Ronald B. Moss Chief Medical Officer
Karen K. Daniels Vice President-Operations
Sector and Competitors
1st jan.Capi. (M$)
ADAMIS PHARMACEUTICALS CORPORATION116.45%156
JOHNSON & JOHNSON4.75%431 543
ROCHE HOLDING AG10.05%322 644
PFIZER, INC.19.40%246 414
NOVO NORDISK A/S50.62%232 291
ELI LILLY AND COMPANY37.51%206 972